Actavis Starts its Business in Ireland
Entering the Irish market last week, Actavis plans to create up to 25 new local jobs over the next five years and to launch more than 120 generic drugs in Ireland, with the potential to save millions of euro off the country’s annual health bill.
The new roles Actavis will create are in addition to 11 corporate employees currently based in Ireland.
“Over the next five years, we plan to rapidly expand our offering in Ireland in all channels-hospital-specific, prescription, and over the counter medicines,” says Actavis Ireland Managing Director Tony Hynds.
The arrival of Actavis into the Irish market, Hynds said, came at a time when the country was struggling to meet the rapidly rising cost of
healthcare.“In Ireland, Actavis has established a team with deep expertise in the local industry, people who understand the nature of the market here, and has given them the backing of a vast global product pipeline,” Hynds added.
Actavis launched a generic cancer treatment drug, Gemcitabine, on the Irish market last Monday. It was made available for prescription from 9th March, on day one when the patent for Gemcitabine expired in Ireland.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Zenocutuzumab Shows Durable Efficacy in NRG1 Fusion-Positive Cancers in Phase II eNRGy Trial
February 13th 2025The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 fusion–positive cancers, particularly non-small cell lung cancer and pancreatic cancer.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
